Skip to main content
. 2012 Sep 18;17(11):1351–1375. doi: 10.1634/theoncologist.2012-0311

Table 5.

Summary of clinicopathologic characteristics of patients with ALK-rearranged NSCLC and clinical activity of crizotinib in patients enrolled in the first in-human trial (PROFILE 1001) over a period of 4 years

graphic file with name onc01112-1185-t05.jpg

aMean.

Abbreviations: CI, confidence interval; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; NR, not reported; PFS, progression-free survival; ORR, overall response rate; SD, stable disease.